Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12326
- Acceso en línea:
- https://doi.org/10.1016/j.intimp.2020.106928
http://hdl.handle.net/20.500.12010/12326
- Palabra clave:
- COVID-19
SARS-CoV-2
Immunopathogenesis
Vaccines
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido
| id |
UTADEO2_ffd50e357c451191c8a60ab8cbf91e6c |
|---|---|
| oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12326 |
| network_acronym_str |
UTADEO2 |
| network_name_str |
Expeditio: repositorio UTadeo |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| title |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| spellingShingle |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine COVID-19 SARS-CoV-2 Immunopathogenesis Vaccines Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| title_short |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| title_full |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| title_fullStr |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| title_full_unstemmed |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| title_sort |
Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| dc.subject.spa.fl_str_mv |
COVID-19 SARS-CoV-2 Immunopathogenesis Vaccines |
| topic |
COVID-19 SARS-CoV-2 Immunopathogenesis Vaccines Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| dc.subject.lemb.spa.fl_str_mv |
Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| description |
Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non‐existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production. |
| publishDate |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2020-08-26T17:27:14Z |
| dc.date.available.none.fl_str_mv |
2020-08-26T17:27:14Z |
| dc.date.created.none.fl_str_mv |
2020 |
| dc.type.local.spa.fl_str_mv |
Artículo |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.identifier.issn.spa.fl_str_mv |
1567-5769 |
| dc.identifier.other.spa.fl_str_mv |
https://doi.org/10.1016/j.intimp.2020.106928 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/12326 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/j.intimp.2020.106928 |
| identifier_str_mv |
1567-5769 |
| url |
https://doi.org/10.1016/j.intimp.2020.106928 http://hdl.handle.net/20.500.12010/12326 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_f1cf |
| dc.rights.local.spa.fl_str_mv |
Acceso restringido |
| rights_invalid_str_mv |
Acceso restringido http://purl.org/coar/access_right/c_f1cf |
| dc.format.extent.spa.fl_str_mv |
45 páginas |
| dc.format.mimetype.spa.fl_str_mv |
image/jepg |
| dc.publisher.spa.fl_str_mv |
International Immunopharmacology |
| dc.source.spa.fl_str_mv |
reponame:Expeditio Repositorio Institucional UJTL instname:Universidad de Bogotá Jorge Tadeo Lozano |
| instname_str |
Universidad de Bogotá Jorge Tadeo Lozano |
| institution |
Universidad de Bogotá Jorge Tadeo Lozano |
| reponame_str |
Expeditio Repositorio Institucional UJTL |
| collection |
Expeditio Repositorio Institucional UJTL |
| bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/1/Captura.PNG https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/3/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/4/Captura.PNG https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/5/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpg |
| bitstream.checksum.fl_str_mv |
7e8d822a41004d203655052198b1dff3 eccfca9470d95b67801b4a03986b55df abceeb1c943c50d3343516f9dbfc110f 7e8d822a41004d203655052198b1dff3 d7ba685b924cf1ce97a2a7d7e825d6f6 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
| repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
| _version_ |
1814213809088233472 |
| spelling |
2020-08-26T17:27:14Z2020-08-26T17:27:14Z20201567-5769https://doi.org/10.1016/j.intimp.2020.106928http://hdl.handle.net/20.500.12010/12326https://doi.org/10.1016/j.intimp.2020.106928Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non‐existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.45 páginasimage/jepgengInternational Immunopharmacologyreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoCOVID-19SARS-CoV-2ImmunopathogenesisVaccinesSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusOverview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccineArtículohttp://purl.org/coar/resource_type/c_2df8fbb1Acceso restringidohttp://purl.org/coar/access_right/c_f1cfMirzaei, RasoulMohammadzadeh, RokhsarehMahdavi, FarzadBadrzadeh, FaribaKazemi, SheidaEbrahimi, MehdiSoltani, FatemehKazemi, SimaSalimi Jeda, AliDarvishmotevalli, MohammadYousefimashouf, RasoulKeyvani, HosseinKarampoor, SajadORIGINALCaptura.PNGCaptura.PNGVer portadaimage/png150206https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/1/Captura.PNG7e8d822a41004d203655052198b1dff3MD51open accessOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfArtículo reservadoapplication/pdf1281025https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/3/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfeccfca9470d95b67801b4a03986b55dfMD53embargoed access|||2200-08-26LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILCaptura.PNGCaptura.PNGPortadaimage/png150206https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/4/Captura.PNG7e8d822a41004d203655052198b1dff3MD54open accessOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgIM Thumbnailimage/jpeg11722https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/5/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgd7ba685b924cf1ce97a2a7d7e825d6f6MD55open access20.500.12010/12326oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/123262020-08-26 12:29:12.815open accessRepositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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 |